ESC congress – a success for Cardioskin

By October 10, 2018news

• A dedicated corner for WeHealth at the ESC Congress in Munich, on August 25

The congress of the European Society of Cardiology is the largest medical congress in Europe with more than 30,000 active participants !
Thanks to a great booth design and a huge commitment of the whole team, we had a huge visibility both internally and externally during the whole congress.
We were able to present to the visitors our first partnerships and our ambition: Work in open innovation with start-ups to find new e-health solutions that improve care for patients and everyday life for healthcare professionals.


• A considerable success for our first partnerships

Cardioskin®, HomeHeart®, Mobiosense, and Betterise have successfully raised the interests of many doctors.


– CardioSkin®, when a t-shirt can monitor your heart

Cardioskin, ready to market, is a CE marked and 510k FDA US Clearance noninvasive medical device which allows ECG home monitoring and ambulatory diagnosis from a few days to several weeks. It is a simple system composed of 15 leads embedded in an innovative textile connected to an acquisition module that records an ECG signal. This module does an analog-digital conversion and sends the signal wirelessly to the cloud where the data are stored in a secure way but easily accessible to the treating physician who can make a more accurate and timely diagnosis without bringing the patient to the hospital.
Cardioskin ensures flexibility during the whole duration of the monitoring period, and a better patient acceptability.


– Homeheart, when a drop a blood can predict heart failure

CardioRenal and WeHealth by Servier have formed a partnership to develop HomeHeart® (early stage of development). It’s a unique tele-medicine device capable of detecting early signs of heart failure with a simple drop of blood. It aims at reducing rehospitalizations for patients suffering from heart failure.

– Mobiosense and Betterise

Even though they are still in development phase, these two cardiology and diabetes products have aroused the interest and many opportunities emerged for future developments or business.


We are thrilled to see how WeHealth has conveyed the image of innovation and patient‐centricity thanks to the display of innovative solutions, a lot of meetings and appointments, interviews with journalists or even the presence on social media.